SEC Form 4 · accession 0001140361-16-075795

CytomX Therapeutics, Inc. · CTMX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Aug 9, 2016

Accepted (ET)

Aug 11, 2016 · 12:29 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001501989

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Aug 9, 2016	M	31,767	$1.1339	A	179,558	D
Common Stock	Aug 9, 2016	M	16,612	$0.945	A	196,170	D
Common Stock	Aug 9, 2016	M	27,606	$1.4489	A	223,776	D
Common Stock	Aug 9, 2016	M	17,139	$1.5749	A	240,915	D
Common Stock^F1	holding	—	—		—	331,643	I	By Frederick W. Gluck 1997 Family Trust dtd July 28, 1997
Common Stock^F2	holding	—	—		—	22,111	I	By Richlin Partners, LLC
Common Stock	holding	—	—		—	3,200	I	By spouse

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Stock Option (right to buy)^F3	$1.1339	Aug 9, 2016	M	31,767	D	—	Mar 23, 2021	Common Stock	31,767	D
Stock Option (right to buy)^F3	$0.945	Aug 9, 2016	M	16,612	D	—	Feb 25, 2023	Common Stock	16,612	D
Stock Option (right to buy)^F3	$1.4489	Aug 9, 2016	M	27,606	D	—	May 23, 2024	Common Stock	27,606	D
Stock Option (right to buy)^F3	$1.5749	Aug 9, 2016	M	17,139	D	—	Feb 8, 2025	Common Stock	17,139	D

F1The Reporting Person is a trustee of Frederick W. Gluck 1997 Family Trust dtd July 28, 1997.
F2Richlin Partners, LLC is an entity owned of record by the spouse of the Reporting Person.
F3100% of the shares subject to the option are fully vested and exercisable.